Subscribe To
Lexeo therapeutics announces pricing of initial public offering
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage ...
November 3, 2023, 1:51 am
Gold’s consolidation: bullish continuation or impending correction?
Gold’s consolidation near trend highs suggests a potential breakout, with strong underlying demand setting the ...
November 2, 2023, 8:21 pm
Pantheon vision raises $2.5 million in seed funding to launch development of bioengineered corneal implant
The medical device startup is focused on addressing significant unmet needs of patients suffering from corneal blindness around the world BALTIMORE, M...
November 2, 2023, 6:06 pm
Regenxbio: biotech to watch with 2 possible accelerated approval pathways
Regenxbio Inc. is making progress in its pipeline, aiming to have five gene therapies in late-stage tes...
November 2, 2023, 5:33 pm
Genfit to present update on scientific and corporate progress at the liver meeting® 2023
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 2 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-...
November 2, 2023, 5:10 pm
Starbucks unveils plan to add 17,000 locations by 2030, cut $3 billion in costs
The announcement marks the latest stage in the company's broader "reinvention" strategy, which was laid...
November 2, 2023, 5:02 pm
Dbv technologies to present new data at acaai 2023
Montrouge, France, November 2, 2023 DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12...
November 2, 2023, 4:30 pm
Gold's consolidation: bullish continuation or impending correction?
Gold's consolidation near trend highs suggests a potential breakout, with strong underlying demand setting the ...
November 2, 2023, 4:21 pm
Pagerduty scoops up incident management startup jeli.io
PagerDuty announced this afternoon that it intends to acquire Jeli.io, an early stage incident manageme...
November 2, 2023, 4:05 pm
Kura oncology and mirati therapeutics enter into clinical collaboration and supply agreement to evaluate ko-2806 and adagrasib in krasᴳ¹²ᶜ-mutated nsclc
– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024 – SAN DIE...
November 2, 2023, 11:30 am
Lucid diagnostics to present at canaccord genuity medtech, diagnostics, and digital health & services forum
Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in New York NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq...
November 2, 2023, 9:18 am
In8bio to present new positive data from phase 1 trial of inb-100 at 2023 american society of hematology (ash) annual meeting
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceut...
November 2, 2023, 9:17 am
Corvus pharmaceuticals to present new interim soquelitinib data from its phase 1/1b t cell lymphoma trial at the 65th american society of hematology (ash) annual meeting & exposition
BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-...
November 2, 2023, 9:15 am
Ford reports lower us vehicle sales in october
Ford reported a 5.3% drop in total U.S. vehicle sales in October after the United Workers Union (UAW) stage...
November 2, 2023, 9:09 am
Recursion to participate in upcoming investor conference
SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage Te...
November 2, 2023, 8:05 am
Kalvista pharmaceuticals to present data at the 2023 annual scientific meeting of the american college of allergy, asthma & immunology
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical ...
November 2, 2023, 6:30 am
Gbp to usd forecast: the bank of england takes center stage
GBP/USD analysis: Bank of England’s pivotal decision and US labor market focus in the spotlight. The post GBP to USD Forecast: The Bank of England T...
November 2, 2023, 5:30 am
Bt backs outlook after modest rise in second quarter sales
BT Group PLC (LSE:BT.A) backed full-year guidance after reporting flat revenue and a slight rise in earnings at the half-way ...
November 2, 2023, 3:33 am
Molecular partners to present initial data from ongoing phase 1/2a trial of mp0533 for patients with relapsed/refractory aml and aml/mds at the 65th ash annual meeting and exposition
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (...
November 2, 2023, 2:00 am
Unlock exclusive perks with lightning motorcycle’s green revolution
Lightning Motorcycle is building mind-blowing, audacious electric vehicles for the real world. Lightning aims to offer superior efficiency, performanc...
November 2, 2023, 1:06 am